Product Information
APREPITANT 125 MG CAPSULE is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $114.0440 per EA under NDC 68462058576. Its NADAC has been published 94 times since Dec 18, 2024.
FDA first approved this application on Oct 12, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
125 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462058576
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
APREPITANTApproval Type
Generic (ANDA)
FDA Application
ANDA207777FDA Approved
10/12/2017
TE Code
AB
On Market Since
10/12/2017
Pharmacological Classes
Price Statistics
The NADAC for APREPITANT 125 MG CAPSULE has been published 94 times since Dec 18, 2024, and over the history we have for it it has declined 37.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $114.0440 per EA |
|---|---|
| All-time high | $199.2198 (Sep 10, 2025) |
| All-time low | $114.0440 (Sep 23, 2026) |
| 52-week high | $178.3444 |
| 52-week low | $114.0440 |
| Median price | $170.7756 |
| Average price | $157.6571 |
| Largest weekly change | -11.9% (Jan 21, 2026) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aprepitant market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Substance P/Neurokinin-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of APREPITANT 125 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for APREPITANT 125 MG CAPSULE, manufactured by Glenmark Pharmaceuticals Inc., USA, is $114.0440 per EA (NDC 68462058576), effective Sep 30, 2026.
How has the price of APREPITANT 125 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for APREPITANT 125 MG CAPSULE has declined 37.4%. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for APREPITANT 125 MG CAPSULE?
Since Dec 18, 2024, the NADAC for APREPITANT 125 MG CAPSULE has ranged from a low of $114.0440 (Sep 23, 2026) to a high of $199.2198 (Sep 10, 2025), with a median of $170.7756 per EA.
Are there cheaper alternatives to APREPITANT 125 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as APREPITANT 125 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures APREPITANT 125 MG CAPSULE?
APREPITANT 125 MG CAPSULE (NDC 68462058576) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.